CRCatherine Roche-Lestienne

Catherine Roche-Lestienne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine Roche-Lestienne has a total of 591 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Involvement of the JAK‐STAT pathway in the molecular landscape of tyrosine kinase fusion‐negative hypereosinophilic syndromes: A nationwide CEREO study

    by Matthieu Groh, Laurène Fenwarth, Mathilde Labro, Augustin Boudry, Elise Fournier, Mathieu Wemeau, Alice Marceau‐Renaut, Rafael Daltro de Oliveira, Julie Abraham, Marly Barry, et al.

    We investigated using a custom NGS panel of 149 genes the mutational landscape of 64 consecutive adult patients with tyrosine kinase fusion‐negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive of myeloid neoplasm. At least one mutation was reported in 50/64 (78%) patients (compared to 8/44 (18%) patients with idiopathic HE/HES/HEUS used as controls; p < .001). Thirty‐five patients (54%) had at least one mutation involving the JAK‐STAT pathway, including STAT5B (n = 18, among which the hotspot N642H, n = 13), JAK1 (indels in exon 13, n = 5; V658F/L, n = 2), and JAK2 (V617F, n = 6; indels in exon 13, n = 2). Other previously undescribed somatic mutations were also found in JAK2, JAK1, STAT5B, and STAT5A, including three patients who shared the same STAT5A V707fs mutation and features consistent with primary polycythemia. Nearly all JAK‐STAT mutations were preceded by (or associated with) myelodysplasia‐related gene mutations, especially in RNA‐splicing genes or chromatin modifiers. In multivariate analysis, neurologic involvement (hazard ratio [HR] 4.95 [1.87–13.13]; p = .001), anemia (HR 5.50 [2.24–13.49]; p < .001), and the presence of a high‐risk mutation (as per the molecular international prognosis scoring system: HR 6.87 [2.39–19.72]; p < .001) were independently associated with impaired overall survival. While corticosteroids were ineffective in all treated JAK‐STAT‐mutated patients, ruxolitinib showed positive hematological responses including in STAT5A‐mutated patients. These findings emphasize the usefulness of NGS for the workup of tyrosine kinase fusion‐negative HE/HES patients and support the use of JAK inhibitors in this setting. Updated classifications could consider patients with JAK‐STAT mutations and eosinophilia as a new “gene mutated‐entity” that could be differentiated from CEL, NOS, and idiopathic HES.


  • Phenotypic spectrum of SHANK2-related neurodevelopmental disorder

    by Roseline Caumes, Thomas Smol, Caroline Thuillier, Marie Balerdi, Catherine Lestienne-Roche, Sylvie Manouvrier-Hanu, Jamal Ghoumid


  • Open Access

    Lessons from the analysis of TAD boundary deletions in normal population

    by Thomas Smol, Jérôme Sigé, Caroline Thuillier, Frédéric Frénois, Perrine Brunelle, Mélanie Rama, Catherine Roche-Lestienne, Sylvie Manouvrier-Hanu, Florence Petit, Jamal Ghoumid

    Topologically Associating Domains (TAD)-boundaries induce spatial constraints, allowing interaction between regulatory elements and promoters only within their TAD. Their disruption could lead to disease, through gene-expression deregulation. This mechanism has been shown in only a relatively low number of diseases and a relatively low proportion of patients, raising the possibility of TAD boundary disruption without phenotypical consequence. We investigated, therefore, the occurrence of TAD boundaries disruption in the general population. Coordinates of 307,430 benign deletions from public databases were crossed with 36 Hi-C datasets. Differences in gene content and gene localization were compared in the TADs, according to the possible disruption of their boundaries by a deletion found in the general population. TADs with no deletion encompassing their boundaries (R-TAD) represented 38% of TADs. Enrichment in OMIM genes as well as in morbid genes was observed in R-TADs and genes in R-TADs were found to localize closer to the boundaries. Our results support recent publications tempering the impact of breaking TADs on gene expression with a majority of broken TADs in the general population. A subgroup of R-TAD emerges from this analysis with enrichment in disease genes and their coordinates could be used to annotate CNV from pangenomic approaches to enhance data interpretation.


  • Open Access

    Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia

    by Audrey Bidet, Stéphanie Dulucq, Thomas Smol, Alice Marceau-Renaut, Stéphane Morisset, Valérie Coiteux, Marie-Pierre Noël-Walter, Franck-Emmanuel Nicolini, Isabelle Tigaud, Isabelle Luquet, et al.

    Clonal chromosome abnormalities in Philadelphia negative cells could concern chronic myeloid leukaemia patients treated by tyrosine kinase inhibitors. The European Leukemia Net distinguishes -7/del(7q) abnormalities as a 9warning9. However, the prognosis of clonal chromosome abnormalities in Philadelphia negative cells, and specifically those of -7/del(7q), on clinical outcomes is unclear and based on case-reports showing morphological dysplasia and increased risk of acute myeloid leukaemia, suggesting the coexistence of chronic myeloid leukemia and high-risk myelodysplastic syndrome. We aim to determine whether the impact of -7/del(7q) clonal chromosome abnormalities in Philadelphia negative cells on the clinical outcome is different from the others type of abnormalities, and we argue for an underlying associated high-risk myelodysplastic syndrome. From 102 chronic myeloid leukemia patients with clonal chromosome abnormalities in Philadelphia negative cells with more than median of 6 years follow-up, patients with -7/del(7q) present more frequently signs of dysplasia, lower cumulative incidence of MR4.5 and often need further treatment lines, thus impacting EFS and PFS. Morphological features of dysplasia are associated with myelodysplastic syndrome/acute myeloid leukemia mutations and compromise the optimal response to tyrosine kinase inhibitors, irrespectively of the type of clonal chromosome abnormalities in Philadelphia negative cells. However NGS mutations patterns could not clearly explain the underlying high-risk disease. We hereby confirm the pejorative prognostic value of -7/del(7q) CCA/Ph- and suggest that myelodysplastic features constitute a warning signal for optimal tyrosine kinase inhibitor response.


  • Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

    by Delphine Rea, Shanti Ame, Marc Berger, Jean‐Michel Cayuela, Aude Charbonnier, Valérie Coiteux, Pascale Cony‐Makhoul, Viviane Dubruille, Stéphanie Dulucq, Gabriel Etienne, et al.

    BACKGROUND: The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off‐treatment response after treatment discontinuation; this situation is called treatment‐free remission (TFR). Knowledge accumulated during the last 10 years justifies moving TFR strategies from research to clinical practice.METHODS: Twenty experts from the French Chronic Myeloid Leukemia Study Group (France Intergroupe des Leucémies Myéloïdes Chroniques), including 17 hematologists, 2 molecular biologists, and 1 cytogeneticist, critically reviewed published data with the goal of developing evidence‐based recommendations for TKI discontinuation in clinical practice.RESULTS: Clinically relevant questions were addressed, including the selection of candidate patients (with known prognostic factors for outcomes taken into account), detailed monitoring procedures during the treatment‐free phase, a definition of relapse requiring therapy resumption, and monitoring after treatment reintroduction.CONCLUSIONS: This work presents consensus statements with the aim of guiding physicians and biologists by means of pragmatic recommendations for safe TKI discontinuation in daily practice. Cancer 2018;124:2956‐63. © 2018 American Cancer Society.


  • MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype

    by T. Smol, F. Petit, A. Piton, B. Keren, D. Sanlaville, A. Afenjar, S. Baker, E. C. Bedoukian, E. J. Bhoj, D. Bonneau, et al.

    Molecular anomalies in MED13L, leading to haploinsufficiency, have been reported in patients with moderate to severe intellectual disability (ID) and distinct facial features, with or without congenital heart defects. Phenotype of the patients was referred to “MED13L haploinsufficiency syndrome.” Missense variants in MED13L were already previously described to cause the MED13L-related syndrome, but only in a limited number of patients. Here we report 36 patients with MED13L molecular anomaly, recruited through an international collaboration between centers of expertise for developmental anomalies. All patients presented with intellectual disability and severe language impairment. Hypotonia, ataxia, and recognizable facial gestalt were frequent findings, but not congenital heart defects. We identified seven de novo missense variations, in addition to protein-truncating variants and intragenic deletions. Missense variants clustered in two mutation hot-spots, i.e., exons 15–17 and 25–31. We found that patients carrying missense mutations had more frequently epilepsy and showed a more severe phenotype. This study ascertains missense variations in MED13L as a cause for MED13L-related intellectual disability and improves the clinical delineation of the condition.


  • Open Access

    TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

    by Stéphanie Poulain, Christophe Roumier, Elisabeth Bertrand, Aline Renneville, Aurélie Caillault-Venet, Emmanuelle Doye, Sandrine Geffroy, Sheherazade Sebda, Olivier Nibourel, Morgane Nudel, et al.

    Purpose: TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little is known regarding TP53 alteration in Waldenstrom's macroglobulinemia (WM). Experimental Design: Here, we have explored the incidence of TP53 alteration using Sanger sequencing and ultradeep-targeted sequencing in 125 WM and 10 immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS), along with the clinical features and the associated genomic landscape using single-nucleotide polymorphism array and mutational landscape in an integrative study. Results: Overall, we have identified alteration of TP53 locus including mutation, deletion, and copy-neutral LOH in 11.2% of WM. TP53 mutation was acquired in 7.3% of patients with WM at diagnosis, being absent in IgM MGUS, and was highly correlated to deletion 17p. No correlation with CXCR4 mutations was observed. Patients with TP53 alteration had a greater number of genomic abnormalities. Importantly, WM with TP53 alteration had a significantly shorter overall survival, particularly in symptomatic WM, and independently of the international prognostic scoring system for Waldenstrom macroglobulinemia (IPSSWM) score. Specific treatment for WM with TP53 may have to be studied. Nutlin-3a–targeted p53 signaling induced cytotoxicity preclinically, along with new compounds such as ibrutinib, PrimaMet, or CP31398 that bypass p53 pathway in WM, paving the path for future treatment-tailored options. Conclusions: Our results highlight the clinical significance of detection of TP53 alteration in WM to determine the prognosis of WM and guide the treatment choice. Clin Cancer Res; 23(20); 6325–35. ©2017 AACR.


  • Open Access

    t(11;17)(p15;q21) involving the NUP98 gene is a rare event in adult acute myeloid leukemia.

    by Nicolas Duployez, Stéphanie Struski, Catherine Roche-Lestienne

    Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST-CNRS OPEN ACCESS JOURNAL t(11;17)(p15;q21) involving the NUP98 gene is a rare event in adult acute myeloid leukemia.


  • Open Access

    The t(2;12)(p12;p13), leading to the juxtaposition of the cyclin D2 CCND2 gene with the immunoglobulin kappa locus (IGK), defines a small subset of mantle cell lymphomas lacking cyclin D1 expression.

    by Nicolas Duployez, Laurent Pascal, Judith Bruge, Marie Fatoux, Catherine Roche-Lestienne

    Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST-CNRS OPEN ACCESS JOURNAL The t(2;12)(p12;p13), leading to the juxtaposition of the cyclin D2 CCND2 gene with the immunoglobulin kappa locus (IGK), defines a small subset of mantle cell lymphomas lacking cyclin D1 expression.


  • Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma

    by Salomon Manier, Daisy Huynh, Yu J. Shen, Jia Zhou, Timur Yusufzai, Karma Z. Salem, Richard Y. Ebright, Jiantao Shi, Jihye Park, Siobhan V. Glavey, et al.

    Targeting translation initiation in multiple myeloma induces inhibition of a specific oncogenic translation program.